Paratek Sees Broad Potential For Omadacycline After Second Phase III Win
Executive Summary
Paratek Pharmaceuticals will seek US FDA approval for omadacycline in early 2018 based on a second successful Phase III study for its antibiotic. The company believes the drug has broad potential against multiple pathogens and across multiple patient populations.
You may also be interested in...
Paratek's Antibiotic Nuzyra Survived 20 Years – Now For The US Launch
Company still mulling pricing for broad-spectrum antibiotic Nuzyra (omadacycline), which is set to launch in the US in the first quarter, following FDA approval Oct. 2.
Paratek's Omadacycline Get US Panel OK, But CABP Mortality Remains Concern
Most FDA advisory committee members say potential mortality issue seen in community acquired bacterial pneumonia patients can be addressed postmarket.
Paratek's Omadacycline May Face Mortality Questions With Proposed Pneumonia Indication
US FDA advisory committee will consider "noteworthy" imbalance in deaths in Paratek's trial in community-acquired bacterial pneumonia; agency could not determine cause, briefing documents note.